Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.

Janoueix-Lerosey I, Lequin D, Brugières L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, Valteau-Couanet D, Frebourg T, Michon J, Lyonnet S, Amiel J, Delattre O.

Nature. 2008 Oct 16;455(7215):967-70. doi: 10.1038/nature07398.

PMID:
18923523
2.

Oncogenic mutations of ALK kinase in neuroblastoma.

Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, Wang L, Soda M, Kikuchi A, Igarashi T, Nakagawara A, Hayashi Y, Mano H, Ogawa S.

Nature. 2008 Oct 16;455(7215):971-4. doi: 10.1038/nature07399.

PMID:
18923524
3.

Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients.

Passoni L, Longo L, Collini P, Coluccia AM, Bozzi F, Podda M, Gregorio A, Gambini C, Garaventa A, Pistoia V, Del Grosso F, Tonini GP, Cheng M, Gambacorti-Passerini C, Anichini A, Fossati-Bellani F, Di Nicola M, Luksch R.

Cancer Res. 2009 Sep 15;69(18):7338-46. doi: 10.1158/0008-5472.CAN-08-4419. Epub 2009 Sep 1.

4.

Oncogenic mutations of ALK in neuroblastoma.

Ogawa S, Takita J, Sanada M, Hayashi Y.

Cancer Sci. 2011 Feb;102(2):302-8. doi: 10.1111/j.1349-7006.2010.01825.x. Review.

5.

Identification of ALK as a major familial neuroblastoma predisposition gene.

Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, Laureys G, Speleman F, Kim C, Hou C, Hakonarson H, Torkamani A, Schork NJ, Brodeur GM, Tonini GP, Rappaport E, Devoto M, Maris JM.

Nature. 2008 Oct 16;455(7215):930-5. doi: 10.1038/nature07261. Epub 2008 Aug 24.

6.

Activating mutations in ALK provide a therapeutic target in neuroblastoma.

George RE, Sanda T, Hanna M, Fröhling S, Luther W 2nd, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, Xue L, Zozulya S, Gregor VE, Webb TR, Gray NS, Gilliland DG, Diller L, Greulich H, Morris SW, Meyerson M, Look AT.

Nature. 2008 Oct 16;455(7215):975-8. doi: 10.1038/nature07397.

7.

High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours.

Carén H, Abel F, Kogner P, Martinsson T.

Biochem J. 2008 Dec 1;416(2):153-9.

PMID:
18990089
8.

The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.

Kelleher FC, McDermott R.

Eur J Cancer. 2010 Sep;46(13):2357-68. doi: 10.1016/j.ejca.2010.04.006. Epub 2010 May 5. Review.

PMID:
20451371
9.

High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma.

Schulte JH, Bachmann HS, Brockmeyer B, Depreter K, Oberthür A, Ackermann S, Kahlert Y, Pajtler K, Theissen J, Westermann F, Vandesompele J, Speleman F, Berthold F, Eggert A, Brors B, Hero B, Schramm A, Fischer M.

Clin Cancer Res. 2011 Aug 1;17(15):5082-92. doi: 10.1158/1078-0432.CCR-10-2809. Epub 2011 Jun 1.

10.

Germline gain-of-function mutations of ALK disrupt central nervous system development.

de Pontual L, Kettaneh D, Gordon CT, Oufadem M, Boddaert N, Lees M, Balu L, Lachassinne E, Petros A, Mollet J, Wilson LC, Munnich A, Brugière L, Delattre O, Vekemans M, Etchevers H, Lyonnet S, Janoueix-Lerosey I, Amiel J.

Hum Mutat. 2011 Mar;32(3):272-6. doi: 10.1002/humu.21442.

PMID:
21972109
11.

All-trans retinoic acid downregulates ALK in neuroblastoma cell lines and induces apoptosis in neuroblastoma cell lines with activated ALK.

Futami H, Sakai R.

Cancer Lett. 2010 Nov 28;297(2):220-5. doi: 10.1016/j.canlet.2010.05.014. Epub 2010 Jun 23.

PMID:
20576349
12.

PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma.

Bachetti T, Di Paolo D, Di Lascio S, Mirisola V, Brignole C, Bellotti M, Caffa I, Ferraris C, Fiore M, Fornasari D, Chiarle R, Borghini S, Pfeffer U, Ponzoni M, Ceccherini I, Perri P.

PLoS One. 2010 Oct 1;5(10). pii: e13108. doi: 10.1371/journal.pone.0013108.

13.

Inhibition of N-linked glycosylation impairs ALK phosphorylation and disrupts pro-survival signaling in neuroblastoma cell lines.

Del Grosso F, De Mariano M, Passoni L, Luksch R, Tonini GP, Longo L.

BMC Cancer. 2011 Dec 22;11:525. doi: 10.1186/1471-2407-11-525.

14.

Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy.

Martinsson T, Eriksson T, Abrahamsson J, Caren H, Hansson M, Kogner P, Kamaraj S, Schönherr C, Weinmar J, Ruuth K, Palmer RH, Hallberg B.

Cancer Res. 2011 Jan 1;71(1):98-105. doi: 10.1158/0008-5472.CAN-10-2366. Epub 2010 Nov 8.

16.

The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking.

Mazot P, Cazes A, Boutterin MC, Figueiredo A, Raynal V, Combaret V, Hallberg B, Palmer RH, Delattre O, Janoueix-Lerosey I, Vigny M.

Oncogene. 2011 Apr 28;30(17):2017-25. doi: 10.1038/onc.2010.595. Epub 2011 Jan 17.

PMID:
21242967
17.

Clinical feature of anaplastic lymphoma kinase-mutated neuroblastoma.

Ogura T, Hiyama E, Kamei N, Kamimatsuse A, Ueda Y, Ogura K.

J Pediatr Surg. 2012 Oct;47(10):1789-96. doi: 10.1016/j.jpedsurg.2012.05.007.

PMID:
23084186
18.
19.

Anaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells.

Schönherr C, Yang HL, Vigny M, Palmer RH, Hallberg B.

Oncogene. 2010 May 13;29(19):2817-30. doi: 10.1038/onc.2010.27. Epub 2010 Mar 1.

PMID:
20190816
20.

Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma.

Trochet D, Bourdeaut F, Janoueix-Lerosey I, Deville A, de Pontual L, Schleiermacher G, Coze C, Philip N, Frébourg T, Munnich A, Lyonnet S, Delattre O, Amiel J.

Am J Hum Genet. 2004 Apr;74(4):761-4. Epub 2004 Mar 11.

Supplemental Content

Support Center